Bausch Health Companies Inc. (NYSE:BHC) Receives $7.75 Average PT from Analysts

Bausch Health Companies Inc. (NYSE:BHC) has been given an average recommendation of “Hold” by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $7.75.

A number of equities research analysts recently commented on BHC shares. Truist Financial lowered their price target on Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Jefferies Financial Group lowered their price target on Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. Piper Sandler lowered Bausch Health Companies from a “neutral” rating to an “underweight” rating and decreased their target price for the company from $9.00 to $3.00 in a research report on Friday, August 2nd. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. Finally, Raymond James initiated coverage on Bausch Health Companies in a research report on Wednesday, July 10th. They set a “market perform” rating and a $8.00 target price for the company.

Insider Transactions at Bausch Health Companies

In other news, EVP Seana Carson sold 13,370 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the transaction, the executive vice president now owns 435,198 shares in the company, valued at approximately $2,702,579.58. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.12% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co boosted its stake in Bausch Health Companies by 4.1% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 88,457 shares of the company’s stock worth $933,000 after purchasing an additional 3,519 shares during the period. Bfsg LLC boosted its stake in Bausch Health Companies by 46.7% in the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after purchasing an additional 3,643 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Bausch Health Companies by 6.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 60,706 shares of the company’s stock worth $423,000 after purchasing an additional 3,923 shares during the period. Blair William & Co. IL boosted its stake in Bausch Health Companies by 5.0% in the 1st quarter. Blair William & Co. IL now owns 84,245 shares of the company’s stock worth $894,000 after purchasing an additional 4,000 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in Bausch Health Companies by 2.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock worth $1,719,000 after purchasing an additional 4,944 shares during the period. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Down 5.3 %

Shares of NYSE:BHC opened at $9.26 on Friday. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The stock’s 50 day moving average is $7.55 and its 200-day moving average is $7.05. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -20.08 and a beta of 0.74.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. The business had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative return on equity of 850.93% and a negative net margin of 1.88%. Bausch Health Companies’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.03 EPS. Equities research analysts anticipate that Bausch Health Companies will post 3.6 earnings per share for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.